Skip to content

Ketamine for depression: all studies

Page 83 of 154: studies 821 to 830 of 1,534, newest first. Back to the ketamine for depression overview

Research

Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression.

Cureus April 1, 2024 Mitchell B. Liester, Rachel Wilkenson, Barry Patterson et al. 3 citations

Borderline personality disorder (BPD) and treatment-resistant depression (TRD) are common mental disorders that are challenging to treat. Ketamine is an N-methyl-D-aspartate receptor antagonist that has shown promise as a rapid-acting antidepressant when administered intravenously. BPD symptoms have also been demonstrated to improve with repeated intravenous administration of ketamine, and a...

DOI: 10.7759/cureus.57654 (opens in new tab) Full text (opens in new tab) Ampa receptor Brain-derived neurotrophic factor Glutamate dysregulation Low dose ketamine +6

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.

Journal of Affective Disorders April 1, 2024 Sabrina Wong, Angela T H Kwan, Kayla M Teopiz et al. 19 citations

Inadequate outcomes with monoamine-based treatments in depressive disorders are common and provide the impetus for mechanistically-novel treatments. Esketamine is a proven treatment recently approved for adults with Treatment-Resistant Depression (TRD) while psilocybin is an investigational treatment. Translation of the clinical meaningfulness for these foregoing agents in adults with TRD is...

Ketamine and epigenetic processes in depression, intersection between serotonergic and glutamatergic pathways

Journal of Psychedelic Studies March 29, 2024 Arghavan Nepton, Hesam Farahani, Monnica T. Williams et al. 2 citations

Abstract Background Hypotheses surrounding the etiology of depressive disorders encompass a wide range of biological changes that can occur in a depressed individual, from gene variations to epigenetic modifications and not only serotonergic mechanisms. Once again, the therapy response of the patient to antidepressants is connected to modifications in the epigenetic regulation of genes within...

Effect of Acute Ketamine Treatment on Sympathetic Regulation Indexed by Electrodermal Activity in Adolescent Major Depression.

Pharmaceuticals (Basel, Switzerland) March 10, 2024 Veronika Kovacova, Andrea Macejova, Ingrid Tonhajzerova et al. 4 citations

Ketamine is a potential rapid-onset antidepressant characterized by sympathomimetic effects. However, the question of ketamine's use in treating adolescents' major depressive disorder (MDD) is still discussed. Thus, we aimed to study the acute effect of ketamine infusion treatment on sympathetic regulation using electrodermal activity (EDA) in addition to an assessment of depressive...

DOI: 10.3390/ph17030358 (opens in new tab) Full text (opens in new tab) Major depressive disorder Adolescence Depressive symptomatology Electrodermal activity +12

Fabrication of a Controlled-Release Core-Shell Floating Tablet of Ketamine Hydrochloride Using a 3D Printing Technique for Management of Refractory Depressions and Chronic Pain.

Polymers March 8, 2024 Tahmineh Karami, Emad Ghobadi, Mohammad Akrami et al. 13 citations

In this study, a novel floating, controlled-release and core-shell oral tablet of ketamine hydrochloride (HCl) was produced using a dual extrusion by 3D printing method. A mixture of Soluplus® and Eudragit® RS-PO was extruded by a hot-melt extrusion (HME) nozzle at 150-160 °C to fabricate the tablet shell, while a second nozzle known as a pressure-assisted syringe (PAS) extruded the etamine HCl...

DOI: 10.3390/polym16060746 (opens in new tab) Full text (opens in new tab) Ketamine 3d printing Additive manufacturing Extended release +7

Perioperative Adjunctive Esketamine for Postpartum Depression Among Women Undergoing Elective Cesarean Delivery

JAMA Network Open March 6, 2024 Yu Chen, Yu Guo, Han Wu et al. 63 citations

Importance Postpartum depression (PPD) is one of the most common mental health conditions during the perinatal and postpartum periods, which can have adverse effects on both mother and infant. Objective To investigate the efficacy of perioperative adjunctive esketamine administration after cesarean deliveries in the prevention of PPD. Design, Setting, and Participants A single-center,...

DOI: 10.1001/jamanetworkopen.2024.0953 (opens in new tab) Full text (opens in new tab) Postpartum-depression Cesarean-section Mental-health Maternal-health +1

A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide.

Psychopharmacology Bulletin March 4, 2024 Timothy Whitaker, Kimberly F Farrand, Michael E. Thase 249 citations

Despite the prevalence of Major Depressive Disorder (MDD) and the propensity of affected individuals to eventually die by suicide, there is no therapeutic approved specifically for suicidal ideation and behavior (SI/B) in MDD. The NMDA receptor antagonist ketamine has been investigated for the treatment of depression and shown to have a rapid effect on symptoms. Spravato® (esketamine) is...

Depression-like phenotypes in mice following common bile duct ligation: Insights into the gut-liver-brain axis via the vagus nerve.

Neurobiology of Disease March 1, 2024 Yong Yang, Akifumi Eguchi, Chisato Mori et al.

Depression frequently occurs in patients with liver cirrhosis, yet the reasons for this correlation are not fully understood. Dysbiosis of gut microbiota has been implicated in depression through the gut-brain axis via the vagus nerve. This study explored the potential role of the gut-liver-brain axis via the vagus nerve in depression-like phenotypes in mice with liver cirrhosis. These mice...

Loss of the sustained antidepressant-like effect of (2R,6R)-hydroxynorketamine in NMDA receptor GluN2D subunit knockout mice.

Journal of Pharmacological Sciences March 1, 2024 Aimi Yamagishi, Yuiko Ikekubo, Masayoshi Mishina et al. 6 citations

Ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, has attracted attention for its acute and sustained antidepressant effects in patients with depression. Hydroxynorketamine (HNK), a metabolite of ketamine, exerts antidepressant effects without exerting ketamine's side effects and has attracted much attention in recent years. However, the detailed pharmacological mechanism of action...

DOI: 10.1016/j.jphs.2024.01.008 (opens in new tab) Full text (opens in new tab) Glun2d Hydroxynorketamine Tail-suspension test Depression treatment +3

Formulary Coverage of Esketamine and Ketamine for Depression in Ohio Health Insurance Marketplace and Medicaid Plans.

Journal of Psychiatric Practice March 1, 2024 Brian S. Barnett 5 citations

For more than 2 decades, intravenous ketamine has been demonstrated to have rapid antidepressant effects. However, access to this generic drug is limited due to insurers claiming it is "experimental" because ketamine does not have a Food and Drug Administration indication for depression. In contrast, intranasal esketamine, an enantiomer of ketamine, is approved by the Food and Drug...

DOI: 10.1097/PRA.0000000000000766 (opens in new tab) Full text (opens in new tab) Ketamine therapy Mental health insurance Depression treatment Healthcare coverage +1